RT info:eu-repo/semantics/article
T1 Differential transcriptome profile of peripherals white cells to identify biomarkers involved in oxaliplatin induced neuropathy
A1 Morales González, Manuel José
A1 Ávila, Julio
A1 González-Fernández, Rebeca
A1 Boronat, Laia
A1 Soriano, María Luisa
A1 Martín-Vasallo, Pablo
A2 Medicina InternaDermatología y Psiquiatría
K1 transcriptome profile
K1 chemotherapy
K1 oxaliplatin
K1 neuropathy
K1 FOLFOX
K1 CAPOX
K1 colon-adenocarcinoma
AB Anticancer chemotherapy (CT) produces non-desirable effects on normalhealthy cells and tissues. Oxaliplatin is widely used in the treatment of colorectal cancerand responsible for the development of sensory neuropathy in varying degrees, fromcomplete tolerance to chronic neuropathic symptoms. We studied the differential geneexpression of peripheral leukocytes in patients receiving oxaliplatin-based chemotherapy tofind genes and pathways involved in oxaliplatin-induced peripheral neuropathy.Circulating white cells were obtained prior and after three cycles of FOLFOX or CAPOXchemotherapy from two groups of patients: with or without neuropathy. RNA was purified,and transcriptomes were analyzed. Differential transcriptomics revealed a total of 502genes, which were significantly up- or down-regulated as a result of chemotherapy treatment. Nine of those genes were expressed in only one of two situations: CSHL1, GH1,KCMF1, IL36G and EFCAB8 turned off after CT, and CSRP2, IQGAP1, GNRH2, SMIM1and C5orf17 turned on after CT. These genes are likely to be associated with the onsetof oxaliplatin-induced peripheral neuropathy. The quantification of their expression inperipheral white cells may help to predict non-desirable side effects and, consequently,allow a better, more personalized chemotherapy.
SN 2075-4426
YR 2014
FD 2014
LK http://riull.ull.es/xmlui/handle/915/40038
UL http://riull.ull.es/xmlui/handle/915/40038
LA en
DS Repositorio institucional de la Universidad de La Laguna
RD 28-nov-2024